Abstract: The present invention refers to the use of a sodium channel blocker such as tetrodotoxin or saxitoxin, their analogues and derivatives as well as their physiologically acceptable salts, in medicinal products for human therapeutics for the treatment of peripheral-nervously derived neuropathic pain.

Abstract: The present invention refers to the use of a sodium channel blocker such as tetrodotoxin or saxitoxin, their analogues and derivatives as well as their physiologically acceptable salts, in medicinal products for human therapeutics for the treatment of central-nervously derived neuropathic pain.

Abstract: A pharmaceutical analgesic composition comprising an opioid analgesic agent and a compound that binds to the SS1 or SS2 subunit of a sodium channel, such as tetrodotoxin and saxitoxin, and analogs thereof. Administration of an opioid analgesic agent and a compound that binds to the SS1 or SS2 subunit of a sodium channel, such as tetrodotoxin and saxitoxin, and analogs thereof, produces analgesia in the treatment of pain in mammals.

Abstract: A pharmaceutical analgesic composition comprising an opioid analgesic agent and a compound that binds to the SS1 or SS2 subunit of a sodium channel, such as tetrodotoxin and saxitoxin, and analogs thereof. Administration of an opioid analgesic agent and a compound that binds to the SS1 or SS2 subunit of a sodium channel, such as tetrodotoxin and saxitoxin, and analogs thereof, produces analgesia in the treatment of pain in mammals.

Abstract: The present invention relates to a new process of purifying tetrodotoxin using high performance liquid chromatograph technology.

Abstract: The composition of the present invention comprises a sodium channel blocking compound which is capable of specifically binding to a site, either on an SS1 region or an SS2 region, on an extracellular region of a sodium channel alpha subunit, and a pharmaceutically acceptable carrier.

Abstract: The present invention relates to a new process of extracting tetrodotoxin from the tissues of an organism. The invention provides increased yield of tetrodotoxin from animal tissues. In the invention, a lixiviated solution is obtained by soaking the tissues with water and a weak organic acid. Soluble proteins are removed by heating the lixiviated solution at a temperature below the boiling point. After pH adjustment, the solution is passed through a cation exchange column. Inorganic salts and alkaline amino acids are removed, and then the tetrodotoxin is adsorbed and eluted from activated carbon. The tetrodotoxin is crystallized by adjusting the pH to 8-10.

Abstract: A pharmaceutical analgesic composition comprising an opioid analgesic agent and a compound that binds to the SS1 or SS2 subunit of a sodium channel, such as tetrodotoxin and saxitoxin, and analogs thereof. Administration of an opioid analgesic agent and a compound that binds to the SS1 or SS2 subunit of a sodium channel, such as tetrodotoxin and saxitoxin, and analogs thereof, produces analgesia in the treatment of pain in mammals.

Abstract: The invention relates to a system for extracting toxins from biological tissues. The system comprises a lixiviator, an ion-exchange column, a diatomaceous silica-active carbon column, and a vacuum concentrator. Twenty to one hundred kilograms of raw material can be processed at one time when puffer fish ovaries are used as the starting material.

Abstract: The composition of the present invention comprises a sodium channel blocking compound which is capable of specifically binding to a site, either on an SS1 region or an SS2 region, on an extracellular region of a sodium channel alpha subunit, and a pharmaceutically acceptable carrier.

Abstract: The present invention relates to a new process of purifying tetrodotoxin using high performance liquid chromatograph technology.

Abstract: This invention relates to a method of producing analgesia in a mammal experiencing pain by systemically administering an effective amount of a composition comprising essentially of a sodium channel blocking compound, in a suitable pharmaceutical vehicle, to alleviate the pain.

Abstract: The invention relates to a system for extracting toxins from biological tissues. The system comprises a lixiviator, an ion-exchange column, a diatomaceous silica-active carbon column, and a vacuum concentrator. Twenty to one hundred kilograms of raw material can be processed at one time when puffer fish ovaries are used as the starting material.